Orfadin oral suspension 4mg/ml ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
241	Hypertyrosinemia type I	2

241. Hypertyrosinemia type I

---

Clinical trials : 14 /  Drugs : 7 - (DrugBank : 1) / Drug target gene : 1 - Drug target pathways : 5

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-002286-36-DE (EUCTR)	19/11/2012	03/08/2012	Taste and palatability of Orfadin suspension.	Taste and palatability of Orfadin suspension. An open, non-controlled 3-day study in pediatric patients with hereditary tyrosinemia type 1 treated with Orfadin.	Hereditary tyrosinemia type 1 (HT-1) MedDRA version: 14.1;Level: LLT;Classification code 10069459;Term: Tyrosinaemia type I;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]	Product Name: Orfadin oral suspension 4mg/ml INN or Proposed INN: Nitisinone	Swedish Orphan Biovitrum AB	NULL	Not Recruiting			Female: yes Male: yes	18		Germany;United Kingdom
2	EUCTR2012-002286-36-GB (EUCTR)	04/10/2012	10/08/2012	Taste and palatability of Orfadin suspension.	Taste and palatability of Orfadin suspension. An open, non-controlled 3-day study in pediatric patients with hereditary tyrosinemia type 1 treated with Orfadin.	Hereditary tyrosinemia type 1 (HT-1) MedDRA version: 14.1;Level: LLT;Classification code 10069459;Term: Tyrosinaemia type I;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]	Product Name: Orfadin oral suspension 4mg/ml INN or Proposed INN: NITISINONE	Swedish Orphan Biovitrum AB	NULL	Not Recruiting			Female: yes Male: yes	18		Germany;United Kingdom